IPO News Archive
Talecris Biotherapeutics quiet period ends November 9

11/4/09


Talecris Biotherapeutics, former Bayer maker of plasma-derived protein therapies LBO'd by Cerberus, will see its quiet period end on Nov. 9. On September 30, 2009, the company raised $950 million by offering 50 million shares at $19.00, within the expected range of $18.00 to $20.00. Morgan Stanley, Goldman Sachs, and Citi acted as lead managers on the deal.

View IPO Profile: TLCR         
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest